The Australian Medicines Administration (TGA) has approved a drug developed by
The microbiome-based product will first belaunched as a frozen syringe formulation that can be administered through the colon. The company also plans to develop and market enemas and capsules for oral administration (swallowing) in the near future.
Microbiome-based therapies helprestore the microbial ecology of patients' intestines or intestinal bacteria, leading to the treatment of various infectious diseases. This is usually done with a fecal microbiota transplant – the transfer of microbes from the intestines of a healthy person (donor) to a patient. Previously, Hi-Tech talked about research into this treatment method.
Pseudomembranous colitis is a severea disease of the rectum, which is caused by the infectious bacterium Clostridioides difficile and is usually associated with the destruction of the intestinal microflora due to long-term use of antibiotics. Fecal microbiota transplantation has been shown to be over 80% effective in treating this disease.
The developers believe that the creationalternative forms of "delivery" of donor feces will increase the availability of this method of treatment. In contrast to the traditional approach, patients will be able to use medicinal enemas and pills on their own without going to a specialized medical center.
Read more:
Named the consequences of a gas leak from the "Nord Stream"
A massive impact from a space object triggered the Earth's magnetic field
Named the main danger of snoring: scientists told how it affects the brain